0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD4

CD4

CD4 Molecule Information

Name:T-cell surface antigen CD4
Target Synonym:T-cell surface antigen T4/Leu-3;T-cell surface glycoprotein CD4;CD4;CD_antigen=CD4
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:43
Lastest Research Phase:Approved

CD4 Protein Product ListCompare or Buy

CD4 Molecule Synonym Name

CD4,CD4mut,LEU3

CD4 Molecule Background

Cluster of Differentiation 4 (CD4) is also known as T-cell surface antigen T4/Leu-3 (LEU-3) and CD4mut, is a single-pass type I  membrane glycoprotein,and is a member of the immunoglobulin superfamily. CD4 expressed on the surface of T helper cells, monocytes, macrophages, and dendritic cells. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell: D1 and D3 resemble immunoglobulin variable (IgV) domains. D2 and D4 resemble immunoglobulin constant (IgC) domains. CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the tyrosine kinase lck, which is essential for activating many molecules involved in the signaling cascade of an activated T cell. CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain. The extracellular domain adopts an immunoglobulin-like beta-sandwich with seven strands in 2 beta sheets, in a Greek key topology. CD4 has also been shown to interact with SPG21, Lck and Protein unc-119 homolog. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

CD4 References

CD4 Related Molecule

CD4 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ibalizumab-uiyk 5AB; Hu5A8; TMB-355; TNX-355 Approved Biogen, TaiMed Biologics, Theratechnologies TROGARZO fda TAIMED BIOLOGICS USA 2018-03-06 HIV infection Details

CD4 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD4 monoclonal antibody (Immunotech) Phase Ⅱ Immunotech HIV infection Details
F-105 F-105 Phase Ⅰ Centocor HIV infection Details
EC-18 EC-18 Phase Ⅱ Enzychem Lifesciences Neutropenia Details
PRO-542 PRO-542 Phase Ⅱ Columbia University, Progenics Pharmaceutical HIV infection Details
GEN-009 GEN-009 Phase Ⅱ Genocea Biosciences Solid tumours Details
ITV 1(Nonindustrial source) ITV-1 Phase Ⅲ Nonindustrial source, Immunotech Laboratories, Synexa Life Sciences HIV infection Details
Cedelizumab Phase Ⅱ Ortho-McNeil Autoimmune diseases, Transplant rejection Details
TMB-365 TMB-365 Phase Ⅰ TaiMed Biologics HIV infection Details
802-2 802-2; Anti-CD4 802-2; cnscqic-cyclic Phase Ⅱ Thomas Jefferson University, Synthetic Biologics Graft versus host disease Details
Radiolabeled anti-CD4 monoclonal antibody fragment (Biotectid) EP-1645 Phase Ⅱ BIOTECTID Carotid stenosis, Rheumatoid arthritis (RA) Details
Zanolimumab HuMaxCD4; MDX-CD4; MDX-016 Phase Ⅲ Genmab, Emergent BioSolutions Cutaneous T cell lymphoma (CTCL), Rheumatoid arthritis (RA) Details
Anti-CD4 monoclonal antibody 4162W94 Phase Ⅱ GlaxoSmithKline Rheumatoid arthritis (RA) Details
Clenoliximab IDEC 151; SB-217969,SB 217969 Phase Ⅱ Biogen Idec Psoriasis, Rheumatoid arthritis (RA), Asthma Details
HIV-1 peptide vaccine (microparticulate/monovalent, UBI) Phase Ⅰ United Biomedical HIV infection Details
RAP-102 RAP-102; KLH-RAP 101,RAP 102,RAP102 Phase Ⅰ RAPID Pharmaceuticals HIV infection, Multiple sclerosis (MS) Details
VRC-HIVMAB091-00-AB N6LS; VRC-HIVMAB091-00-AB; Z258‐N6LS Phase Ⅰ National Institute of Allergy and Infectious Diseases HIV infection Details
IT-1208 (Kyowa Hakko Kirin) IT-1208 Phase Ⅰ Kyowa Hakko Kirin, Ono Pharmaceutical Solid tumours Details
VRC-HIVAAV070-00-GT AAV8-VRC07 Phase Ⅰ National Institute of Allergy and Infectious Diseases HIV infection Details
CEL-1000 CEL-1000 Preclinical CEL-SCI Malaria, West nile virus infection, Smallpox infection, HBV infection, Venezuelan equine encephalitis virus infection, Herpes simplex virus (HSV) infection Details
T-allo-10 T-allo-10 Phase Ⅰ Stanford University Graft versus host disease Details
CD4-directed chimeric antigen receptor engineered T-cells (Stony Brook University) CD4CAR Phase Ⅰ Stony Brook University School of Medicine, University of Louisville, iCell Gene Therapeutics Leukemia, T cell lymphoma Details
HuB-F5 antibody (Diaclone) Phase Not Specified Tepnel Pharma Rheumatoid arthritis (RA) Details
CALRLong36 peptide (Herlev Hospital) Phase Ⅰ Herlev Hospital Myeloproliferative neoplasms Details
BG-8962 BG-8962 Phase Ⅰ National Institute of Allergy and Infectious Diseases HIV infection Details
Anti-CD4 idiotype vaccine (Nonindustrial source) Phase Ⅱ Nonindustrial source HIV infection Details
Priliximab CEN-000029; cMT-412; MT-412 Phase Ⅱ Centocor Rejection in heart transplantation, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Crohn's disease, Non-Hodgkin's lymphoma (NHL) Details
3BNC-117 3BNC-117 Phase Ⅱ Rockefeller University HIV infection Details
Anti-CD4 monoclonal antibody (Tolerx) TRX-1 (Tolerx); MTRX-1011A; RG-7424 Phase Ⅰ University of Oxford, Genentech, Tolerx Cutaneous lupus erythematosus, Autoimmune diseases, Rheumatoid arthritis (RA) Details
RB-0003 RB-0003 Phase Ⅱ BioNTech, TRON Melanoma Details
Tregalizumab BT-061; hB-F5 Phase Ⅱ Biotest, Abbvie, Boehringer Ingelheim Plaque psoriasis, Rheumatoid arthritis (RA) Details
R-95288 R-95288; SA-1080; S-1443; RKS-1443,R 95288; SA 1080; S 1443; RKS 1443,R95288; SA1080; S1443; RKS1443 Phase Ⅰ Daiichi Sankyo HIV infection Details
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) CAR-C34ZFN Phase Ⅰ University of Pennsylvania HIV infection Details
VRC-01-LS VRC-HIVMAB-080-00-AB; VRC-01-LS Phase Ⅰ National Institute of Allergy and Infectious Diseases, Xencor HIV infection Details
RBC-CD4 (Sheffield Medical Technologies) Phase Ⅱ Sheffield Pharmaceuticals HIV infection Details
Keliximab SB-210396; IDEC-CE9.1,SB 210396 Phase Ⅲ Biogen, GlaxoSmithKline Rheumatoid arthritis (RA), Asthma Details
VRC-07-523 VRC-07-523; VRC-07-523-L S; VRC-HIVMAB-075 -00-AB; VRC-HIVMAB075-00-AB Phase Ⅰ National Institutes of Health HIV infection Details
Anti-CD3 anti-CD20 bispecific antibody (Genmab) GEN-3013 Phase Ⅱ Genmab hematological malignancies Details
UB-421 dB4; mAb-B4; UB-421 Phase Ⅲ United Biomedical, United BioPharma HIV infection Details
HIV vaccines polytope (Bavarian Nordic/VaxOnco) EP-1232; EP-1233; MVA-BN32; MVA-mBN32 Phase Ⅱ Bavarian Nordic, KAEL-GemVax HIV infection Details
AVR-01 AVR-01 Phase Ⅰ AVROBIO Acute myeloid Leukemia (AML) Details
3-BNC-117-LS (Rockefeller University) 3-BNC-117-LS Phase Ⅰ Rockefeller University HIV infection Details
MVA-EL MVA-EBNA1/LMP2 Phase Ⅱ Cancer Research UK, Chinese University of Hong Kong (CUHK) Nasopharyngeal cancer Details
T cell gene therapy (Cell Genesys) Phase Ⅱ Cell Genesys HIV infection, Colorectal cancer Details

This web search service is supported by Google Inc.

totop